Nuclear Medicine News | Telix Scores Another Win—Completes Its Third Acquisition of a Nuclear Medicine Company in 2024

Telix Pharmaceuticals Limited (Telix) announced, on April 11, the completion of its acquisition of ARTMS Inc. (ARTMS), following its February 8 announcement of the acquisition of QSAM Biosciences—whose lead investigational drug is Samarium-153-DOTMP (153Sm-DOTMP)—and its February 26 agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics). This acquisition further strengthens Telix’s vertical integration across its supply chain and manufacturing capabilities, delivering enhanced supply-chain control and regulatory oversight over critical isotope production. ARTMS will support Telix’s portfolio—including commercially important medical isotopes such as 89Zr, 68Ga, 99mTc, and 64Cu—with efficient, large-scale, and cost-effective production. ARTMS will continue collaborating with other radiopharmaceutical companies to ensure these critical isotopes remain readily available for patients. Moreover, ARTMS’s advanced cyclotron technology platform positions it to produce high-value alpha-emitting therapeutic isotopes—including 225Ac and 211At—in the future. ARTMS traces its origins to a Canadian government–funded project focused on solid-target production of 99mTc. Upon successful completion of that project, innovation continued, leading to the development of a full suite of PET products. In 2017, ARTMS Inc. was founded with seed funding and support from Quark Venture’s Global Health Sciences Fund (GHS), alongside founding institutions TRIUMF, BC Cancer, Lawson Health Research Institute, and the Probe Development Centre.

Telix and ITM Enter Merger Agreement, Giving Birth to a Global Radiopharmaceutical Giant and Ushering in a New Phase of Industrialization for Nuclear Medicine

The global radiopharmaceutical market is undergoing rapid expansion. Novartis currently leads the field, powered by two ¹⁷⁷Lu-based products; meanwhile, multinational pharmaceutical companies—including AstraZeneca, Bristol Myers Squibb, and Eli Lilly—are accelerating their strategic entry into this space through acquisitions of innovative platforms such as Fusion Pharmaceuticals, RayzeBio, and POINT Biopharma. In China, the implementation of the Medium- and Long-Term Development Plan for Medical Isotopes (2021–2035) and the Three-Year Action Plan for High-Quality Development of Nuclear Technology Applications (2024–2026) has accelerated domestic production of medical isotopes. Companies including China Isotope & Radiation Corporation and Dongcheng Pharmaceutical have achieved breakthroughs in production capacity for key radionuclides such as lutetium-177 (¹⁷⁷Lu) and actinium-225 (²²⁵Ac). According to data from Yaodu, over 200 radiolabeled drug candidates (RDCs) are currently under development in China. Against this industrial backdrop, the merger between Telix and ITM is widely viewed as a landmark event—signaling a pivotal shift in competitive dynamics within the radiopharmaceutical sector: from clinical-data-driven head-to-head comparisons of individual products, toward an industrialized contest centered on isotope production capacity, supply-chain security, and global delivery capability. PART 02 Transaction Overview Under the terms of the agreement, Telix will acquire 100% of ITM’s equity on a cash-free/debt-free basis, with a base purchase price of USD 1.65 billion. At closing, Telix will assume approximately USD 302 million in net debt from ITM. ITM shareholders are expected to receive approximately USD 1.25 billion in Telix shares—calculated at a volume-weighted average price (VWAP) of USD 11.841 per share over the 30 trading days prior to signing—totaling 105.8 million shares, to be released in Nasdaq-listed ADR form upon expiration of respective lock-up periods. Additionally, the agreement includes contingent consideration of up to USD 700 million, tied to regulatory approval and commercial milestones for ITM’s core late-stage candidate, ITM-11 (¹⁷⁷Lu-edotreotide). Accordingly, the total transaction value could reach approximately USD 2.35 billion. Following completion, existing Telix shareholders are projected to hold approximately 76.3% of the combined company, while ITM shareholders will hold approximately 23.7%. Dr. Christian Behrenbruch, Managing Director and Group CEO of Telix, stated that this merger represents a defining moment in the industry’s maturation process: “This merger places Telix at the forefront of industry consolidation. ITM is a leader in radioactive isotope production, possessing deep scientific expertise and a proven track record of innovation-driven value creation. We have maintained a close collaborative relationship with ITM for many years, and our management teams share strong alignment on the strategic rationale for this transaction. By integrating complementary strengths, we will create a company with commercial scale, world-leading supply capabilities, and the industry’s most compelling theranostic drug portfolio.” This merger also significantly expands Telix’s late-stage therapeutic pipeline and substantially enhances security of supply for radioactive isotopes.

ENDRA Files S-4 for Proposed Merger with ASP Isotopes Unit Incorporating Renergen Disclosure

Oct 2, 2026

ENDRA filed a Form S-4 registration statement for its proposed merger with Noble Africa, a subsidiary of ASP Isotopes, incorporating material disclosures regarding Renergen and financial impacts.

TradingView

2026-03-31

ASP Isotopes Partners with University of Bristol, Survives Class-Action Lawsuit

2026-04-11

ASP Isotopes Inc Targets Initial Commercial Shipments for Key Isotopes by 2026-2027

2026-04-12

ASP Isotopes Revenue Surge Tests Bullish Growth Narratives Against Deepening Losses

2026-04-13

ASP Isotopes Reports Q4 Revenue Surge Amid Widening Losses

2026-04-13

$333M Cash Backs ASP Isotopes' 2026 Push for First Sales